This study specifically utilized RT4 cells, a well-characterized, non-invasive bladder cancer model, to investigate the impact of proTAME, cisplatin, and gemcitabine on MMP2/MMP9-mediated migration, establishing a foundation for subsequent research using more aggressive bladder cancer models. Here, MMP2 is linked to urinary bladder cancer.